These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2533074)

  • 1. Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.
    Chau NP; Pithois-Merli I; Levenson J; Simon AC
    Eur J Clin Pharmacol; 1989; 37(3):215-20. PubMed ID: 2533074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic antihypertensive treatment with ketanserin versus metoprolol on blood pressure and large arteries' compliance in humans: a cross-over double-blind study.
    De Luca N; Rosiello G; Crispino M; Volpe M; Galletti P; Buzzetti G; Trimarco B
    J Clin Pharmacol; 1988 Apr; 28(4):332-8. PubMed ID: 3292598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ; Saniabadi AR; Hosie J; Lowe GD; Ball SG
    Eur J Clin Pharmacol; 1988; 35(2):123-9. PubMed ID: 3142775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.
    Smits J; van Dorsten F; Struyker Boudier H
    Drugs; 1988; 36 Suppl 1():55-60. PubMed ID: 3149239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritanserin and serotonergic mechanisms in blood pressure and fluid regulation in sheep.
    Nelson M; Coghlan JP; Denton DA; Tresham JJ; Whitworth JA; Scoggins BA
    Clin Exp Pharmacol Physiol; 1987 Jul; 14(7):555-63. PubMed ID: 3124998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of chronic antihypertensive treatment with ketanserin versus metoprolol on blood pressure and compliance of great arteries in man: a double-blind crossover study].
    Crispino M
    Ann Ital Med Int; 1990; 5(4 Pt 2):469-76. PubMed ID: 2102134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S92-4. PubMed ID: 2412069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial and venous effects of serotonin in the forearm of healthy subjects are not age-related.
    Blauw GJ; van Brummelen P; Chang PC; Vermeij P; van Zwieten PA
    J Cardiovasc Pharmacol; 1989 Jul; 14(1):14-21. PubMed ID: 2475705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin and ritanserin can reduce reperfusion-induced but not ischaemia-induced arrhythmias in anaesthetised rats.
    Coker SJ; Ellis AM
    J Cardiovasc Pharmacol; 1987 Oct; 10(4):479-84. PubMed ID: 2444803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic 5-HT2-receptor blockade by ritanserin does not reduce blood pressure in patients with essential hypertension.
    Hedner T; Pettersson A; Persson B
    Acta Med Scand; 1987; 222(4):307-10. PubMed ID: 2892349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin as a modulator of skeletal muscle oxygenation: effects of ketanserin and ritanserin on oxygen pressure distributions.
    Thorborg P; Lund N
    Int J Microcirc Clin Exp; 1989 Apr; 8(2):191-203. PubMed ID: 2499554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ; Reneman RS
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.
    Ferrara LA; Fasano ML; Soro S; Rubba P; Iannuzzi A
    J Clin Pharmacol; 1985 Apr; 25(3):187-92. PubMed ID: 3158674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit.
    Bolt GR; Saxena PR
    Hypertension; 1985; 7(4):499-506. PubMed ID: 2861161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B; Gradin K; Pettersson A; Hedner T
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML; Schenck KW; Kurz KD
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive mode of action of ketanserin.
    Robertson JI; Stott DJ; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S45-7. PubMed ID: 2446069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.